Literature DB >> 24220561

Is antiviral prophylaxis necessary to prevent hepatitis B virus (HBV) reactivation in patients with HBV-resolved infection receiving rituximab-containing chemotherapy?

Shigeru Kusumoto1, Yasuhito Tanaka, Masashi Mizokami, Ryuzo Ueda.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2013        PMID： 24220561     DOI： 10.1200/JCO.2013.52.1278

Source DB:  PubMed          Journal:  J Clin Oncol        ISSN： 0732-183X            Impact factor:   44.544


× No keyword cloud information.
  2 in total

1.  Risk of HBV reactivation in patients with B-cell lymphomas receiving obinutuzumab or rituximab immunochemotherapy.

Authors:  Shigeru Kusumoto; Luca Arcaini; Xiaonan Hong; Jie Jin; Won Seog Kim; Yok Lam Kwong; Marion G Peters; Yasuhito Tanaka; Andrew D Zelenetz; Hiroshi Kuriki; Günter Fingerle-Rowson; Tina Nielsen; Eisuke Ueda; Hanna Piper-Lepoutre; Gila Sellam; Kensei Tobinai
Journal:  Blood       Date:  2018-10-19       Impact factor: 22.113

2.  HBV Reactivation in Patients with Past Infection Affected by Non-Hodgkin Lymphoma and Treated with Anti-CD20 Antibody Based Immuno-Chemotherapy: A Multicenter Experience.

Authors:  Michele Clerico; Irene Dogliotti; Paola Ghione; Vittorio Ruggero Zilioli; Francesco Merli; Barbara Botto; Wael Al Essa; Marcella Battaglini; Daniele Grimaldi; Loretta Cervi; Simone Ragaini; Simone Ferrero; Veronica Peri; Gabriele De Luca; Alfredo Marzano; Federica Cavallo
Journal:  J Pers Med       Date:  2022-02-15
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.